Budimkic, Maja Stefanovic (35315601900)Maja Stefanovic (35315601900)BudimkicPekmezovic, Tatjana (7003989932)Tatjana (7003989932)PekmezovicBeslac-Bumbasirevic, Ljiljana (6506489179)Ljiljana (6506489179)Beslac-BumbasirevicErcegovac, Marko (7006226257)Marko (7006226257)ErcegovacBerisavac, Ivana (6507392420)Ivana (6507392420)BerisavacStanarcevic, Predrag (55353773400)Predrag (55353773400)StanarcevicPadjen, Visnja (55605274200)Visnja (55605274200)PadjenJovanovic, Dejana R. (55419203900)Dejana R. (55419203900)Jovanovic2025-06-122025-06-122016https://doi.org/10.1016/j.clineuro.2015.12.003https://www.scopus.com/inward/record.uri?eid=2-s2.0-84950336274&doi=10.1016%2fj.clineuro.2015.12.003&partnerID=40&md5=c7c5ab1eb39e0fad215f00d82d8b083chttps://remedy.med.bg.ac.rs/handle/123456789/7841Objective There are no data regarding long-term medication persistence in stroke survivors treated with intravenous thrombolysis (IVT), which is one of the most important determinants of treatment success. Our objective was to determine long-term medication persistence in stroke patients treated with IVT. Methods This retrospective observational study included 203 IVT-treated and 197 non-IVT treated patients with acute ischemic strokes (IS) admitted to the Stroke Unit between January 2007 and January 2013. Results During a median follow-up period of 3 years (range 1-7 years), 56 (21.6%) patients in the IVT-group and 62 (23.9%) patients in the non-IVT-group died. There was a higher medication persistence for all secondary stroke prevention medications (anti-thrombotic agents, anti-hypertensive drugs, statins and hypoglycemic drugs) in the IVT-group compared to the non-IVT group (88.7% vs. 69.0%; OR = 3.68, 95% CI = 2.17-6.23). After adjusting for baseline characteristics and possible confounders IVT was the independent predictor of medication persistence (OR = 2.93, 95% CI = 1.48-5.81, p = 0.002). Higher medication persistence was observed in patients with favorable long-term functional outcome, both in the IVT-group (OR = 4.37, 95% CI = 1.83-10.40, p < 0.001) and the non-IVT-group (OR = 3.46, 95% CI = 1.84-6.52, p < 0.001). Conclusion Medication persistence was higher among IVT-treated patients compared to non-IVT-treated patients. The higher rate of non- medication persistence was recorded among patients with more pronounced disabilities after stroke. © 2015 Published by Elsevier B.V.Intravenous thrombolysisMedication persistenceStroke outcome